R&D Should Be Outsourced Overseas To Control Development Costs – HGS CEO
Executive Summary
Drug companies should consider outsourcing R&D work to other countries in light of cost pressures in the U.S., Human Genome Sciences CEO William Haseltine, PhD, said
You may also be interested in...
Merck Sees Chance To “Repatriate” Cash To U.S.; GSK Wants To Ship Out
Merck sees an opportunity to bring back cash to the U.S. should a tax change allowing companies to "repatriate" holdings at foreign subsidiaries be enacted by Congress this year
Merck Sees Chance To “Repatriate” Cash To U.S.; GSK Wants To Ship Out
Merck sees an opportunity to bring back cash to the U.S. should a tax change allowing companies to "repatriate" holdings at foreign subsidiaries be enacted by Congress this year
Novartis To Consider “Off Shoring” Some Corporate Functions To India
Novartis will consider "off shoring" certain corporate functions to India